In line with a chemosensitizing impact of TBL1, sensitivity of TBL1-deficient tumors to gemcitabine was significantly enhanced as indicated by reduced tumor size when compared with shNC-treated cells (Fig4E–G; Supplementary Figs S10B and S11). The gene discussed is TBL1Y; the disease is neoplasm.